Total Payments
$517,599
2023 Payments
$1,500
Companies
11
Transactions
125
Payment Breakdown by Category
Consulting$472,071 (91.2%)
Research$35,046 (6.8%)
Travel$5,997 (1.2%)
Other$2,792 (0.5%)
Food & Beverage$1,693 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $472,071 | 63 | 91.2% |
| Unspecified | $35,046 | 6 | 6.8% |
| Travel and Lodging | $5,997 | 20 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,792 | 5 | 0.5% |
| Food and Beverage | $1,693 | 31 | 0.3% |
Payments by Type
General
$482,553
119 transactions
Research
$35,046
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Acorda Therapeutics, Inc | $306,751 | 43 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $76,939 | 33 | $0 (2022) |
| Osmotica Pharmaceutical Corp. | $59,110 | 4 | $0 (2019) |
| Biogen, Inc. | $30,546 | 3 | $0 (2020) |
| Neurocrine Biosciences, Inc. | $20,028 | 10 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $13,833 | 17 | $0 (2023) |
| Medtronic USA, Inc. | $6,303 | 11 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $3,953 | 1 | $0 (2021) |
| MERZ NORTH AMERICA, INC. | $70.58 | 1 | $0 (2017) |
| Vertical Pharmaceuticals, LLC | $36.85 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,500 | 3 | Alexion Pharmaceuticals, Inc. ($1,500) |
| 2022 | $23,967 | 13 | ACADIA Pharmaceuticals Inc ($12,000) |
| 2021 | $35,539 | 9 | Acorda Therapeutics, Inc ($26,640) |
| 2020 | $71,448 | 13 | ACADIA Pharmaceuticals Inc ($25,000) |
| 2019 | $150,230 | 24 | Osmotica Pharmaceutical Corp. ($59,110) |
| 2018 | $144,019 | 32 | Acorda Therapeutics, Inc ($115,005) |
| 2017 | $90,894 | 31 | Acorda Therapeutics, Inc ($84,233) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/11/2023 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $999.98 | General |
| 07/13/2023 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $333.32 | General |
| 05/12/2023 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $166.66 | General |
| 12/14/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/15/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 11/09/2022 | Acorda Therapeutics, Inc | INBRIJA (Drug) | Consulting Fee | Cash or cash equivalent | $5,109.00 | General |
| Category: Parkinson's Disease | ||||||
| 10/13/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 10/13/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $166.66 | General |
| 09/16/2022 | Acorda Therapeutics, Inc | — | Food and Beverage | In-kind items and services | $11.81 | General |
| 08/16/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 08/16/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $833.30 | General |
| 05/06/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/06/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/18/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 03/17/2022 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,180.00 | General |
| 01/18/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $666.66 | General |
| 12/15/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $3,952.50 | General |
| 12/15/2021 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,666.60 | General |
| 09/15/2021 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $333.32 | General |
| 08/15/2021 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,166.62 | General |
| 07/21/2021 | Acorda Therapeutics, Inc | INBRIJA (Drug) | Consulting Fee | Cash or cash equivalent | $10,360.00 | General |
| Category: PARKINSONS DISEASE | ||||||
| 06/15/2021 | Acorda Therapeutics, Inc | — | Consulting Fee | Cash or cash equivalent | $4,440.00 | General |
| 05/06/2021 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 04/28/2021 | Acorda Therapeutics, Inc | INBRIJA (Drug) | Consulting Fee | Cash or cash equivalent | $11,840.00 | General |
| Category: PARKINSONS DISEASE | ||||||
| 02/15/2021 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $20,546 | 2 |
| Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $10,000 | 1 |
| Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months | Alexion Pharmaceuticals, Inc. | $4,500 | 3 |
About Dr. Matthew Stern, MD
Dr. Matthew Stern, MD is a Neurology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316979461.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Stern, MD has received a total of $517,599 in payments from pharmaceutical and medical device companies, with $1,500 received in 2023. These payments were reported across 125 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($472,071).
Ad
Practice Information
- Specialty Neurology
- Location Philadelphia, PA
- Active Since 07/07/2006
- Last Updated 08/10/2015
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1316979461
Products in Payments
- NUPLAZID (Drug) $64,439
- INBRIJA (Drug) $59,115
- DISEASE EDUCATION (Drug) $12,500
- ACTIVA (Device) $6,215
- ONGENTYS (Drug) $1,100
- VISUALASE (Device) $87.98
- Xeomin (Biological) $70.58
- OSMOLEX ER (Drug) $36.85
- Non-Covered Product (Drug) $28.22
- INGREZZA (Drug) $13.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Philadelphia
Dr. Thomas Leist, M.d, M.D
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Daniel Kremens, M.d., J.d, M.D., J.D
Neurology — Payments: $1.9M
Neurology $1.9M
Dr. Jill Giordano Farmer, Do, DO
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Stephen Silberstein, M.d, M.D
Neurology — Payments: $936,801
Neurology $936,801
Amit Bar-Or
Neurology — Payments: $904,147
Neurology $904,147
Dr. Stephanie Nahas-Geiger, M.d, M.D
Neurology — Payments: $828,295
Neurology $828,295